A patent review of IDO1 inhibitors for cancer (2023 - present): an update
{{output}}
Introduction: Indoleamine 2,3-dioxygenase 1 (IDO1) is a promising target in cancer immunotherapy, yet its application faces significant challenges due to complex mechanisms of action. Recent advancements in IDO1 inhibitors aim to... ...
